CVS Caremark Zepbound Prior Authorization: The 2026 Checklist

Disclosure: Some links on this page are affiliate links. The RX Index may earn a commission at no extra cost to you. It never changes what Caremark's documents say, and it never changes which path we tell you to take.

If your insurance card says Aetna, start in your Aetna member portal — Aetna plans can use different formularies and criteria. If your card says CVS Caremark next to a different insurer's name, or your employer's plan name, you're in the right place.

CVS Caremark Zepbound prior authorization is not one rule. Caremark currently publishes at least three commercial Zepbound or tirzepatide criteria documents, a shared request form, and a separate FEP Blue policy. The one your plan uses changes the criteria, the covered device, and the approval length.

Here's the short version. If Zepbound is on your plan's drug list and your plan uses Caremark's standard commercial criteria, the weight-loss path requires a starting BMI of 30 or higher — or 27 with a weight-related condition such as high blood pressure, type 2 diabetes, or abnormal cholesterol or triglycerides — plus six documented months in a weight-management program before the medicine. If Zepbound is not on your list and your plan uses Caremark's current tirzepatide exception, the request turns on documented proof that Wegovy produced an inadequate response, was not tolerated, or is contraindicated. If you're filing for sleep apnea under the standard commercial criteria, the six-month program rule does not apply.

Three things change the answer: whether your plan covers weight-loss drugs at all, which condition your doctor files under, and October 1, 2026 — the date CVS Caremark says Zepbound returns to its most common commercial formularies for plan sponsors that choose the update and cover weight-management medications.

And here's the part almost nobody tells you. We pulled Caremark's own published Indiana outcome report and ran the numbers. The report does not expose every Zepbound request by drug, so we will not call this your approval rate. But among the five Zepbound product-code rows it does disclose, 41.3% were approved, versus 75.4% across five disclosed Wegovy rows. Same PBM. Same state. Same year. A 34.1-point gap in the rows Caremark chose to publish. The appeal table is even more useful: 58.8% of the appeals recorded in that report were approved.

Jump to the answer you need

• Find the rulebook your plan uses
• Check the BMI, program, and sleep-apnea requirements
• See when Wegovy is required first
• Read Caremark's published outcome data
• Build the packet your doctor has to send
• Decode a denial and choose the right next move
• Compare the current cash paths

Is this page for you?

Read your status first — it changes everything

Log in at caremark.com or the CVS Caremark app, search Zepbound, and read the exact wording. These four results look similar. They are four different problems.

One tip most people miss: if your drug list says one thing and the cost tool says another, ask the pharmacy or Caremark to run a test claim — a real claim submission that returns the actual rejection code. The drug list, your benefit, the prior authorization status, and a claim that actually pays are four separate layers. The test-claim rejection code shows which layer stopped the fill.

What we actually verified

On August 8, 2026, we opened and read these sources:

• Caremark protocol 6192-C — Zepbound prior authorization criteria
• Caremark protocol 6947-C — tirzepatide criteria that cover Mounjaro and Zepbound in one document
• Caremark protocol 6981-A, version 5 — the current tirzepatide formulary exception
• Caremark's Formulary Exception / Prior Authorization Request Form — the shared form your doctor's office may use
• Caremark's 2025 Indiana Annual Utilization Review Report — disclosed request, decision, denial, and appeal counts
• Caremark's FEP Blue policy 5.99.031 — a separate federal-employee rulebook
• CVS Health's May 28, 2026 announcement about the October 1 formulary change
• Federal claim-timing rules at 29 CFR 2560.503-1 and 45 CFR 147.136
• Zepbound's current FDA prescribing information, revised February 2026
• Current Lilly, CMS, and Ro pricing and program pages

What none of these can tell us: which document your plan uses. Your plan's contract with Caremark is not public. We can't see it, and neither can any other website. What we can do is give you the exact questions that pull the answer out of them in one phone call.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Which CVS Caremark Zepbound rulebook is yours?

CVS Caremark publishes at least three commercial Zepbound or tirzepatide criteria documents, one shared request form, and a separate FEP Blue policy. They do not all say the same thing. Your formulary helps select the policy; your diagnosis and records decide whether you meet that policy. Finding the document is the first step, because the criteria, covered device, and approval length can change with it.

First, two words you'll see everywhere on this page.

A formulary is your plan's list of covered drugs. A PBM — pharmacy benefit manager — is the company that runs the prescription side of your insurance. CVS Caremark is a PBM. It builds template drug lists. Your plan sponsor — often your employer — chooses or customizes the list you get.

That's why two people who both “have CVS Caremark” can get completely different answers. It isn't random. It is a plan-design decision.

The five sources you may run into

“Not stated” means the document doesn't answer that question. It does not mean the rule does not exist. We use that label on purpose — filling in a blank with a guess is how pages on this topic get people hurt.

Version 5 tells you exactly which formularies it covers

This is the single most useful thing we found, and it's easy to miss. Document 6981-A version 5 opens with a checklist of Caremark formularies, marked as included or not included.

It applies to: Advanced Control, Advanced Control Formulary Chart, Advanced Control–Choice, Standard Control, Standard Control Formulary Chart, Standard Control–Choice, Value, Value Formulary Chart, and Aetna Fully Insured Advanced Control Formulary Chart.

It does not list itself as applying to: Basic Control, Basic Control Chart, Managed Medicaid Template, Marketplace, Aetna Small Group ACA, Aetna Health Exchange, Aetna Individual Lives, Aetna Fully Insured Advanced Control Formulary, or Aetna Fully Insured Standard Opt-Out.

If you know your formulary's name — it may be on your benefit summary or plan documents — you can compare it with that checklist before your doctor's office files anything.

The three questions that reveal your document

Call the number on your pharmacy card and ask, in this order:

1. “Is Zepbound on my drug list, or is it non-formulary?”
2. “Does my plan cover weight-loss medications at all, or are they excluded?”
3. “What criteria document or reference number applies to my Zepbound request?”

Write down the answers, the representative's name or ID if offered, and the date. Question three is the one nobody asks, and it's the one that ends the guessing.

### Find your document in about a minute Open your Caremark portal and take a screenshot of the Zepbound result. Then call the number on your card and ask the three questions above. Match the answer to the five-source table before your doctor's office submits. Do not send your member ID, date of birth, or medical records to a public tool. Your portal and the number on your card are the right places for that information.

What are the CVS Caremark Zepbound prior authorization requirements?

Caremark's published standard commercial Zepbound criteria have two separate doors with different rules. The weight-loss door requires a starting BMI of 30 or higher — or 27 with a weight-related condition such as high blood pressure, type 2 diabetes, or abnormal cholesterol or triglycerides — plus six documented months in a weight-management program before the drug. The sleep-apnea door requires a sleep study showing an AHI of 15 or more plus a current BMI of 30, with no six-month program requirement listed. Your plan's actual criteria control.

BMI — body mass index — is a number calculated from your height and weight. A 5'6" adult at about 186 pounds sits right at 30. Your doctor's office pulls it from a recorded height and weight.

Here are the two doors side by side, straight out of documents 6192-C and 6947-C.

AHI stands for apnea-hypopnea index. It's the number of breathing pauses or shallow-breathing events per hour of sleep. Fifteen or more falls in the moderate-or-higher range. Caremark's criteria accept polysomnography or a home sleep apnea test done with a technically adequate device.

Three things fall out of that table.

Your progress can't be used against you on the weight-loss door. Caremark's criteria say to use your BMI from before you started any weight-loss medicine when you are transitioning from another drug. So if you were 32 last year, dropped to 28 on another medicine, and now want Zepbound — 32 is the number your doctor should document.

But the sleep-apnea door uses today's BMI. Same drug, same company, opposite time point. Someone who already lost weight can meet the weight-management BMI test and miss the sleep-apnea BMI test.

The door with fewer listed prerequisites expires sooner. Six months for sleep apnea, eight for weight management. That means the sleep-apnea renewal can arrive two months earlier.

One thing that's not a loophole

Zepbound is FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity. That's real medicine, and if you have it, use the real diagnosis and the real sleep study.

But do not go looking for a diagnosis you don't have. Caremark's form warns that a person who knowingly makes a false material statement tied to a claim ultimately paid by a federal or state government can face penalties under federal or state False Claims Acts. A sleep-apnea request without the required sleep-study documentation fails the written criteria anyway.

If you snore heavily, wake up gasping, or someone tells you that you stop breathing at night, tell your doctor. Your clinician can decide whether a sleep evaluation is appropriate.

The quantity rule that causes “too soon to fill” rejections

Both standard criteria documents set the single-dose pen limit at four pens per 21 days for a 28-day fill and 12 pens per 63 days for an 84-day fill. Document 6192-C also sets the KwikPen limit at one KwikPen per 21 days or three per 63 days. Caremark states that the shortened day count is there to allow refill processing time.

Plain version: the published limit builds in about a one-week refill buffer. A claim before day 21 may still be too soon. If a standard 28-day refill rejects on day 21 or later, ask for the exact rejection code instead of assuming the prior authorization failed. The device, quantity, days' supply, or a plan-specific limit may be the real problem.

Does CVS Caremark make you try Wegovy first?

Not everyone — but under Caremark's current tirzepatide exception policy 6981-A, yes. That policy names Wegovy as the available formulary alternative and requires documentation of an inadequate treatment response, intolerance, or contraindication to Wegovy. No fixed trial length is written into the criteria.

That last sentence matters, so read it again.

A fixed “12 to 16 weeks with less than 5% weight loss” rule is not in version 5 of the exception criteria. What the current policy actually requires is:

• You cannot be treated with the formulary alternative, Wegovy, and
• You had an inadequate treatment response, an intolerance, or a contraindication to Wegovy — with documentation.

That's the whole written test in 6981-A. No BMI threshold. No six-month program requirement. No separate stopwatch. If a documented intolerance made your prescriber stop Wegovy, the policy does not add a 12- or 16-week minimum. Do not keep taking a medicine just to satisfy a timer that is not written into the policy; treatment decisions belong to your prescriber.

Something changed, and it explains a year of confusion

Here's a finding we can only give you because we compared two versions of the same document.

An archived 2025 version of policy 6981-A laid out a ladder: Wegovy as the primary alternative, Mounjaro as the secondary alternative, and Zepbound as the non-formulary drug. Its approval block was written for Mounjaro, not Zepbound.

That helps explain older advice saying a Zepbound exception could route to Mounjaro. It does not prove what happened in any one member's claim.

The current version — 6981-A version 5, ©2026 — removed that ladder. It is titled “Tirzepatide Exception,” and it says authorization may be granted for the requested drug when the Wegovy criteria are met.

If you were told last year that a Zepbound exception can only get you Mounjaro, that advice is out of date for plans using the current version. Ask your doctor's office to pull version 5 before filing.

A note on Mounjaro, stated plainly: Mounjaro is FDA-approved for type 2 diabetes. It is not FDA-approved for weight management or sleep apnea. Whether it is appropriate for you is a medical decision for your prescriber, not a coverage shortcut. We're reporting what the coverage documents say.

What good Wegovy documentation looks like

If you need this door, your chart has to show real facts:

• The actual drug and dose
• The actual start and stop dates
• What actually happened — an inadequate response, side effects your prescriber judged intolerable, or a documented medical reason you cannot take it
• Your prescriber's explanation of why Zepbound is being requested instead

Do not ask a clinician to report a trial, a side effect, or a reaction that didn't happen. It's the fastest way to poison every future request on your file, and it's fraud.

What do Caremark's published Zepbound prior authorization numbers show?

Caremark publishes real outcome counts in its 2025 Indiana Annual Utilization Review Report — but the drug tables contain only NDC rows that reached one of the report's top-10 rankings. We found five disclosed Zepbound NDC rows and five disclosed Wegovy NDC rows. Across those five Zepbound rows, 4,772 requests produced 1,970 approvals, 2,775 denials, and 27 pending cases — 41.3% approved. Across the five disclosed Wegovy rows, 5,083 requests produced 3,833 approvals — 75.4%. These are selected published rows, not complete statewide drug totals, a national rate, or your personal odds.

That's the damaging admission that makes the data useful instead of misleading: Caremark gave us real rows, but not a complete Zepbound dataset.

Zepbound, by disclosed product code

An NDC is a National Drug Code — a unique number for a specific product, strength, and package. The dose labels below come from the current Zepbound product listing; the request and decision counts come from Caremark's Indiana report.

The 2.5 mg starter-pen row accounts for 57.6% of the disclosed Zepbound requests and has roughly twice the approved share of the four other disclosed rows. The report does not explain why. It also does not disclose the 12.5 mg Zepbound row in these top-10 tables. So do not turn this pattern into “the starter dose gets approved more easily.” It may reflect the mix of plans, request types, formulary timing, coding, or something else the report does not reveal.

The comparison that matters

A 34.1-point gap in the disclosed rows.

That's not a statement about which drug works better. In 2025, Wegovy was the preferred weight-management GLP-1 on Caremark's common formularies while Zepbound had been removed from those lists. The gap is consistent with that formulary difference, but the report does not prove that formulary status caused every decision.

For scale: those ten disclosed Wegovy and Zepbound rows alone account for 9,855 of the 35,097 prior authorization requests in the report — at least 28.1% of all requests. “At least” matters because other NDC rows may exist outside the published top-10 tables.

The all-drug indication table has a warning for sleep-apnea filings

Caremark also publishes a separate table by diagnosis. That table covers all drugs in the report, not Zepbound alone.

Sleep apnea had the lowest approved share among the weight-related indications listed in that all-drug table and the slowest average initial decision.

Here's our read, and we're labeling it as ours: Caremark's standard Zepbound sleep-apnea criteria require a sleep-study report with a visible AHI. A missing report could be one reason a request fails. But the Indiana report does not connect denial reasons to individual diagnoses, so it cannot prove that missing sleep studies caused the 40.2% result.

The practical move still holds: if you're filing under sleep apnea, get the sleep-study report in your hand, in PDF, with the test date and AHI visible, before anything is submitted.

What this data can't tell you

• It is not a complete drug-wide rate. The medication tables publish selected top-ranked NDC rows.
• It is not a national rate. One state, one year.
• It is not your personal odds. Your plan, records, indication, request type, and formulary drive your result.
• It doesn't separate first requests from renewals or formulary exceptions.
• It doesn't say why any individual request was denied.
• The diagnosis table is all drugs, not Zepbound-specific.

One number we found and chose not to use

The same report breaks results out by the prescriber's specialty. Requests where the specialty field was “Unspecified” — about 90% of the total — show a 65% approved share. Rows with a named specialty show much lower figures.

Taken at face value, that would say your endocrinologist is a liability. We don't believe that, and we're not publishing it as advice. It looks like a coding artifact, not a real specialty effect. We're mentioning it because we read the whole report, and telling you what we threw out is part of showing our work.

How long does CVS Caremark take to decide a Zepbound prior authorization?

Caremark's 2025 Indiana report puts the average time from receipt to initial decision at 0.27 days — roughly six and a half hours — across 35,097 requests. Appeals averaged 4.18 days. The five disclosed Zepbound rows ranged from 0.24 to 0.53 days. That clock starts when Caremark receives the request; it does not include days your doctor's office spends preparing or holding the packet.

Read that first number again, because it changes what you should do.

Caremark's published average after receipt is about six hours. So when your case appears stuck for days, first find the handoff point instead of guessing.

Ask your doctor's office: “What date and time was the request sent, by what method, and were the chart notes attached?” Then ask Caremark: “What date and time did you receive it, is it complete, and is a decision pending?” The delay can sit with the office, the routing, missing information, or the plan's review process. Make both sides name the timestamp.

The federal outer limits, when they apply

Many private employer plans and health-insurance issuers are subject to federal claims-and-appeals rules. Government plans, church plans, grandfathered plans, Medicare, Medicaid, and other arrangements can follow different rules. Your denial notice and plan document control.

Sources: 29 CFR 2560.503-1, 29 CFR 2590.715-2719, and 45 CFR 147.136.

And here's the lever nobody writes about. Under the federal rule for covered urgent-care claims, the attending provider determines whether the claim is urgent, and the plan must defer to that determination. Caremark's form has an expedited box with a certification line. If waiting would genuinely put your life, health, or ability to regain maximum function at risk, your treating clinician makes that call. It is not a way to skip the line for convenience.

What does your doctor actually have to send?

Caremark uses one shared form for both prior authorizations and formulary exceptions, and its antiobesity section asks nine numbered questions. The form itself says that demographic and drug information alone may not be enough and tells the office to attach relevant clinical documentation.

The document is called the Formulary Exception / Prior Authorization Request Form. Two of its own sentences explain the paperwork problem:

“Solely providing demographic and drug information may not constitute a sufficient request for coverage.”

“Please provide all relevant clinical documentation to support use of this medication.”

The point is simple: a checked box without the records behind it can still fail.

The nine questions, and what answers each one

What counts as the six-month program

It does not have to be a paid commercial program. Caremark's standard criteria describe behavior change, a reduced-calorie eating plan, increased physical activity, and continuing follow-up.

Records that may show those required parts include dated visits with your doctor about weight, dietitian records, an employer or plan wellness program, documented counseling, and weight-and-activity follow-up in your chart. Your plan decides what it accepts.

A lot of people already have useful records and don't know it. If your primary-care chart shows six months of weight-focused visits, ask your doctor to pull the dates. Do not backdate anything, and don't count an app you downloaded but never used.

Which device is on the prescription — this one is sneaky

Three Caremark commercial documents give different answers about which Zepbound products sit inside the policy.

Your prescriber writes a specific device on the prescription — single-dose pen, single-dose vial, or KwikPen. If that product does not match the policy your plan uses, the pharmacy claim can reject even after the clinical request is approved. People read that as “my PA didn't work.” The approval and the product-level claim are separate.

Worth knowing: the KwikPen is the only Zepbound form included in the Medicare GLP-1 Bridge, while two of these three commercial Caremark documents send the KwikPen to the manufacturer program. Same device, opposite treatment, two different programs.

Where it goes

• Electronic prior authorization (ePA) — your prescriber's system sends the clinical questions electronically. The prompts can reduce blank fields, but the office still has to confirm that the right chart notes went with the request.
• Fax: 1-888-836-0730 — printed on Caremark's shared form and current professional PA page
• Caremark professional prior authorization line: 1-800-294-5979

Always use the number on your card, claim response, or denial letter when it differs. Plan-specific routing beats a general number every time.

Copy this into your patient portal

Hi — I'm trying to avoid a missing-information denial on my CVS Caremark request for Zepbound. When your office submits it, could you please include: my diagnosis and ICD-10 code; my baseline and current weight, height, and BMI with dates; documentation of my weight-management program with visit dates; my weight-related conditions and supporting labs or readings if my BMI is under 30; my sleep-study report and AHI if we're filing for sleep apnea; any prior weight medicines with doses, dates, and what happened; and a quantity and device that match the Caremark policy for my plan. Could you also tell me the date it was sent and confirm that the chart notes were attached? Thank you.

### Print the checklist before the appointment Print or save this section from “The nine questions” through “Where it goes.” Hand it to the office or send the portal message before the visit. That is the fastest useful next step on this page.

Should you file now or wait for October 1, 2026?

CVS Health announced on May 28, 2026 that Zepbound will return to its most common commercial formularies as an additional preferred option on October 1, 2026, for plan sponsors that elect to cover weight-management medications. From this page's August 8 verification date, that is 54 days away. For most people, waiting quietly is the wrong move, because the hardest standard weight-management requirement is something you must have done beforehand.

CVS also says plan sponsors that use its template formularies retain discretion to customize coverage. So the drug-list template changes. Your employer's decision might not.

What to do, by where you are today

The 120-day question nobody mentions

Caremark's shared form opens its continuation section with this question:

“Has the patient been receiving the requested drug within the last 120 days?”

Do not turn that checkbox into a rule it does not state. The form does not say that day 121 automatically makes you a new start, cancels continuation status, or brings the six-month program requirement back. It asks the question and leaves the plan to apply its policy.

If you've been off Zepbound while fighting a denial, count your days. Then ask Caremark one direct question before the office submits: “Does my plan treat this request as continuation after this gap, and which written criteria will apply?” Save the answer and date.

The same continuation section asks a second question almost nobody answers: “Has the requested drug been dispensed at a pharmacy and approved for coverage previously by a prior plan?” If you were approved for Zepbound at a former employer, say so and attach the old approval if you have it. Caremark built a box for it.

The question to ask your HR or benefits team

“Did our plan adopt CVS Caremark's October 1, 2026 formulary update that adds Zepbound back, and are weight-loss medications covered or excluded under our plan?”

Save the answer and the date.

After October 1, do this

Recheck the portal. Ask for a fresh test claim for the exact device and dose. Confirm whether an old exclusion is still sitting in the system. Ask whether a new prior authorization is required. Write down what they say.

Why was your CVS Caremark Zepbound prior authorization denied?

A Zepbound denial from Caremark can be one of several different problems wearing the same letter, and the wording tells you which path to investigate. Missing records, clinical criteria, non-formulary status, a preferred-drug step, quantity, a category exclusion, and renewal proof do not have the same fix.

First, something we found in Caremark's Indiana report that will save you a lot of frustration.

The report has a table called “Top 10 Reasons for Denial.” It contains exactly one filled row. All 14,114 denials are categorized as “Does not meet clinical criteria.”

Which means the report's denial category tells you almost nothing about the exact gap in your own case. Call and say: “The denial says the clinical criteria weren't met. Which specific criterion failed, what document was missing or insufficient, and what would satisfy it?”

The denial decoder

Four things not to do

• Don't resubmit the identical packet and hope. Fix the named gap first.
• Don't treat “not covered” and “PA denied” as the same problem. They can have opposite fixes.
• Don't rely on a phone summary when a written denial is available. Get the letter and the criteria reference.
• Don't let the deadline in the letter run out while you decide whether to correct, except, or appeal.

What real people say about this

These are two comments from members in r/Zepbound. They're here because they capture how uneven this process feels — not as evidence about criteria or your chances.

“I resubmitted my PA and it was approved today within 2 days!” — OddlyCongruent

“My pre auth got denied within in hour of submission.” — Easy-Net6069

Both things can happen quickly. Caremark's Indiana report also shows fast average decisions after receipt. But neither the comments nor the report tell us why those two individual requests were approved or denied. Speed alone does not diagnose the problem.

Should you resubmit, request an exception, or appeal?

Resubmit when the original request was incomplete or filed under the wrong path. Request a formulary exception when Zepbound is non-formulary and your plan offers an exception process. Appeal when Caremark had the evidence and your prescriber disputes how the written criteria were applied. Caremark's 2025 Indiana report shows that 1,430 of 14,114 denied requests had an appeal recorded — 10.1% — and 841 of those appeals were approved, or 58.8%.

Let's sit with those two numbers.

About 89.9% of denied requests had no appeal recorded. The recorded appeals were approved more often than they were denied.

That's all drugs, one state, one year — not Zepbound-specific and not a promise. But it is real plan-reported appeal data, and it supports taking the appeal option seriously when your records match the written criteria.

Pick the right tool

Resubmit a corrected request when a field was blank, chart notes weren't attached, dates or weights were missing, the quantity was wrong, or the wrong request path was used. Ask whether Caremark accepts a corrected submission without giving up your appeal rights.

Request a formulary exception when Zepbound is non-formulary, your plan names Wegovy as preferred, and your prescriber can document a real inadequate response, intolerance, or contraindication.

File a clinical appeal when Caremark received the evidence, your prescriber believes it meets the written criteria, and you dispute how the plan applied those criteria. Follow the deadline and instructions printed on your denial notice.

Ask whether a peer-to-peer discussion is available. Caremark publishes a process for arranging a discussion between a prescriber and a clinical peer, but availability and timing can be plan-specific.

If the final internal denial still stands, read the external-review section of the letter. For plans subject to the federal ACA external-review rules, a denial involving medical judgment can qualify for independent external review. The federal request must generally be filed within four months after you receive the adverse decision. A pure benefit exclusion or eligibility dispute may not qualify. Your letter must explain any available process, and state or plan rules can differ.

Escalate to your employer or plan sponsor when the problem is benefit design rather than clinical eligibility.

What a strong appeal contains

Strong appeals are boring and specific:

1. Quote the plan's own criterion and map your evidence to it, line by line. This is the single highest-value thing you can do.
2. A letter of medical necessity: diagnosis, history, what has been tried, and why Zepbound is being requested.
3. Objective records with dates — weights, labs, sleep study, dose history, and fills.
4. The denial letter and the exact document or reference number.
5. Proof it was filed inside the deadline, with copies of everything.

### Build the letter around the plan's own words Put the denial criterion at the top. Under it, list each matching record with its date, then attach the records in that same order. Give your prescriber a clean evidence map instead of a vague “please reconsider” letter.

What if your employer doesn't cover weight-loss drugs at all?

This is the one wall a standard prior authorization can't get through. If your plan excludes weight-management medications as a category, Zepbound is not being denied because you missed a BMI box — the benefit may not exist. The October 1 change updates Caremark's common formularies, not your employer's final plan design.

We'd rather tell you this straight than let you spend six weeks on an appeal aimed at the wrong problem.

The three commercial criteria documents we checked do not create a weight-loss benefit where the plan excludes the category. They describe clinical review paths after the benefit and formulary question is answered. That is why the first question is coverage design, not BMI.

How to tell an exclusion from a non-formulary denial: they look almost identical and have opposite fixes. Ask directly — “Is Zepbound non-formulary on my plan, or are weight-loss medications excluded from my benefit?” Non-formulary means an exception process may exist. Excluded means you need to ask about a benefit exception or another covered indication, not just a drug exception.

Three things that can still work:

1. Ask whether a benefit exception exists anyway. Some plans allow individual benefit exceptions. Ask in writing.
2. Ask how the plan handles the sleep-apnea indication. Do not assume a weight-management exclusion answers the question. Ask whether Zepbound for moderate-to-severe OSA is reviewed under a separate covered benefit and request the written rule.
3. Talk to HR before open enrollment. Employers do change benefits. Ask what it would take and whether the October template update will be adopted.

If none of those apply to you, stop here and go to the cost section. You're not losing — you're switching to a path that can actually work.

What does Zepbound cost if CVS Caremark says no?

If your plan covers the Zepbound single-dose pen, eligible commercially insured patients may pay as little as $25 under Lilly's current savings terms. If commercial insurance does not cover that single-dose pen, Lilly's card lists it as low as $499 for a one-month fill. Lilly's self-pay program lists the Zepbound KwikPen and single-dose vials at $299 for 2.5 mg, $399 for 5 mg, and as low as $449 for 7.5 mg through 15 mg when the higher-dose refill rule is met. The $299 price does not apply to the single-dose pen.

Here's the honest ladder. Our affiliate partner sits where it actually falls.

And we'll say the quiet part: if you already have a willing prescriber and you're paying cash, going straight to LillyDirect is cheaper than adding a membership — and we don't earn a thing when you do that.

Where Ro will not help you

Ro does not control what CVS Caremark decides. Its free insurance checker currently checks the Ozempic pen, Wegovy pen, and Zepbound autoinjector pen. It does not check the Zepbound KwikPen or vial.

So if your plan uses a Caremark document that sends KwikPens to the manufacturer program, if you need a vial, or if the real problem is a category exclusion — Ro's free checker won't answer that product-level question. Your own prescriber's office and the number on your Caremark card are the better first move. Go back to the submission checklist.

For members who enroll in Ro Body and pursue insurance, Ro says its insurance concierge can check coverage and handle prior-authorization paperwork for the Zepbound autoinjector pen. Ro also says that process can take about 2–3 weeks. Caremark still makes the decision.

That's the trade. Not the cheapest. The path where somebody else handles more of the paperwork.

### Does that sound like your situation? Check your Zepbound pen coverage free with Ro → Sponsored link. Ro's free checker covers the Zepbound autoinjector pen, not the KwikPen or vial. A clinician visit is required before any prescription, and no service can guarantee your plan approves coverage. Prefer a different clinician? Compare options on Sesame Care → (sponsored)

One thing you won't find on this page: we don't route anyone here toward compounded tirzepatide. You're fighting for coverage of an FDA-approved medicine. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed. They are not interchangeable with Zepbound, and mixing the two into a coverage decision helps nobody.

Medicare, Medicaid, and federal employees: different rulebooks

If you're on Medicare, Medicaid, or FEP Blue, most of the commercial-plan section above does not apply to you. Medicare has a separate GLP-1 Bridge path for eligible weight-management use, federal employees run on FEP policy 5.99.031, and Medicaid rules are set state by state.

Medicare. The Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2027 and operates outside the normal Part D payment flow. Eligible beneficiaries pay $50 for a monthly fill. For Zepbound, the Bridge includes the KwikPen only — not single-dose pens and not vials — when prescribed for the Bridge's weight-management use. If Zepbound is prescribed for a Part D-coverable indication such as moderate-to-severe OSA, the request goes through the regular Part D plan instead of the Bridge. Full walkthrough here.

FEP Blue. Federal employees fall under Caremark's FEP policy 5.99.031, effective July 1, 2026. For chronic weight management, it adds requirements the commercial documents above do not have — including documented inadequate response, intolerance, or contraindication to at least two oral weight-management medicines; participation in a comprehensive program; no overlapping GLP-1 or other PA weight-loss therapy; and a preferred-product requirement unless a valid medical exception applies. Initial approval runs 6 months; renewal runs 12 months. The policy's quantity table lists 12 single-dose pens per 84 days.

Medicaid. Set by your state, and it changes often. Do not apply the commercial Caremark rules above to a Medicaid plan without checking the state's current policy.

You got approved. Now protect the renewal.

Caremark's standard commercial first approval runs 8 months for weight management or 6 months for sleep apnea. Renewal isn't automatic. The weight-management renewal requires three months at a stable maintenance dose plus at least 5% off your baseline weight, or maintenance of that loss, documented with dates. This is a renewal denial you can prepare for months ahead.

Do these five things this week. It takes about ten minutes total.

1. Write down the baseline weight in your approval records and the date. Everything gets measured against that number.
2. Get follow-up weigh-ins into your clinical chart, not just your phone. The renewal needs documentation the reviewer can verify.
3. Log dose changes with dates. The renewal asks how long you've been at a stable maintenance dose.
4. Keep your fill history. It supports continuation and makes any treatment gap easier to explain.
5. Set a reminder 45 days before your approval expires. Your doctor renews early instead of you rationing medicine during a gap.

If you're on the sleep-apnea path, the renewal is different: the diagnosis and qualifying sleep study still have to stand, you need a maintenance dose, and the record must show improvement in at least one sleep-apnea symptom. Keep clinical notes on daytime sleepiness, snoring, waking episodes, or other symptoms your clinician is tracking. The standard Caremark renewal criteria do not set a weight-loss percentage for that door.

Six months from now, your renewal takes ten minutes instead of three panicked weeks.

What to know before you chase coverage

Coverage and medical suitability are two separate questions, and only one of them gets decided by a form.

We compared the February 2026 FDA label with Caremark documents 6192-C, 6947-C, and 6981-A. All three Caremark documents repeat the warning against using Zepbound with another tirzepatide product or another GLP-1 medicine. None replaces the full FDA safety screen below.

From Zepbound's current FDA prescribing information: do not use it if you or a family member has had medullary thyroid carcinoma, if you have MEN 2, or if you have had a serious allergic reaction to tirzepatide or a Zepbound ingredient. Serious warnings and precautions include severe stomach and intestinal reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar when combined with insulin or certain diabetes medicines, diabetic-retinopathy complications in some people with type 2 diabetes, and aspiration risk during general anesthesia or deep sedation. Zepbound is not recommended with another tirzepatide product or another GLP-1 receptor agonist.

The label says to stop Zepbound when pregnancy is recognized. It also says oral hormonal birth control may work less well after starting Zepbound and after each dose increase; the label advises switching to a non-oral method or adding a barrier method for four weeks after starting and for four weeks after each dose increase. Tell the care team before planned surgery or a procedure with deep sedation.

This isn't the full label. Read the Medication Guide and talk to your prescriber.

Caremark decides whether your plan pays. Your clinician decides whether Zepbound is right for you. A yes on one is not a yes on the other.

How we built and verified this guide

We're The RX Index — independent guidance for choosing your GLP-1 path.

For this page, we opened Caremark's own documents rather than summarizing other websites. We read prior authorization criteria 6192-C and 6947-C, formulary exception policy 6981-A version 5, and the Formulary Exception / Prior Authorization Request Form. We pulled Caremark's 2025 Indiana Annual Utilization Review Report and calculated the selected Zepbound and Wegovy figures ourselves from the NDC rows Caremark disclosed. We read CVS Health's May 28, 2026 announcement, FEP policy 5.99.031, the federal claims-and-appeals rules, CMS's Medicare GLP-1 Bridge materials, Lilly's current price terms, Ro's current program pages, and Zepbound's FDA labeling revised February 2026.

Our Indiana calculation, stated plainly. Caremark's medication section contains separate top-10 tables for request count, approvals, and denials. We collected every unique Wegovy and Zepbound NDC row that appeared in those disclosed tables, counted each NDC once, summed requests, approvals, denials, and pending cases, and divided approvals by requests. Caremark published the rows. The selected-row totals and percentages are ours.

What we could not verify, and will not pretend to know:

• Which document your specific plan uses. Private plan contract. Nobody outside your plan can see it.
• Whether your employer will adopt the October 1 template change.
• Caremark's post-October-1 Zepbound criteria. As of August 8, 2026, the live general criteria files still carry the P08-2025 policy dates shown above.
• A complete Indiana or national Caremark Zepbound approval rate. The report publishes selected NDC rows, not a complete drug extract.
• Why the disclosed 2.5 mg Zepbound row differs from the other doses.
• Why the all-drug sleep-apnea row has a lower approved share.
• What consequence your plan attaches to the 120-day continuation question.

When we'll recheck this. Caremark updates formularies and revises criteria documents. We recheck the criteria and drug list monthly through January 2027, prices monthly, and the FDA labeling quarterly. The date at the top only changes when we've actually rechecked.

Frequently asked questions

Does CVS Caremark require prior authorization for Zepbound?

On plans where Zepbound is covered, prior authorization and quantity limits are common under Caremark's published criteria. On plans where Zepbound is non-formulary, the request may be a formulary exception instead. Check the exact portal wording and ask which policy number governs your plan before your doctor files.

What BMI does CVS Caremark require for Zepbound?

Caremark's published standard commercial weight-management criteria require a baseline BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or abnormal cholesterol or triglycerides. The standard sleep-apnea path uses a current BMI of 30 or higher plus a qualifying sleep study. Other plan-specific policies can differ, so your plan's written criteria control.

Does everyone need six months of weight-management records?

No. That requirement appears in Caremark's standard commercial weight-management criteria and on the shared antiobesity form. It does not appear in the current 6981-A formulary-exception criteria, and it is not listed for the standard sleep-apnea path. Confirm which document governs your request before assuming you need it.

Does CVS Caremark always make you try Wegovy first?

No. The current 6981-A exception policy requires documented inadequate response, intolerance, or contraindication to Wegovy, but that policy applies only to the formularies marked on its first page. No fixed Wegovy trial length is written into version 5.

Why did older Caremark guidance point to Mounjaro instead of Zepbound?

An archived 2025 version of 6981-A listed Wegovy as the primary alternative, Mounjaro as the secondary alternative, and Zepbound as non-formulary. The current version 5 authorizes the requested tirzepatide drug when its Wegovy criteria are met. Ask the office to use the current version.

Does CVS Caremark cover Zepbound for sleep apnea?

It can. Caremark's standard commercial criteria require moderate-to-severe OSA shown by an AHI of at least 15 on a qualifying sleep test, plus a current BMI of at least 30. The Indiana report's all-drug sleep-apnea row had a 40.2% approved share, but that figure is not Zepbound-specific and the report does not say why requests were denied.

How long does CVS Caremark prior authorization take?

Caremark's 2025 Indiana report puts the average at 0.27 days from receipt to initial decision across 35,097 requests, with appeals averaging 4.18 days. The five disclosed Zepbound rows averaged 0.24 to 0.53 days. That does not include time before the office sends the packet. Ask both the office and Caremark for the send and receipt timestamps.

Why was my request denied within an hour?

A fast denial can come from an exclusion, non-formulary rule, missing field, missing attachment, quantity problem, or a clinical-criteria mismatch. The report does not let us identify the cause from speed. Ask which exact criterion failed and get the written denial.

Should my doctor resubmit or appeal?

Resubmit or correct the request when information was missing, the product was wrong, or the wrong path was used. Appeal when Caremark had the evidence and your prescriber disputes how the written criteria were applied. Keep the deadline in the denial letter alive while you correct the file.

Are appeals worth filing?

Caremark's 2025 Indiana data shows that 10.1% of denied requests had an appeal recorded and 58.8% of those appeals were approved. That's all drugs in one state in one year, not a promise. It does show that the recorded appeals were approved more often than denied.

What if my drug list says covered but the cost tool says not covered?

Ask Caremark or your pharmacy to run a test claim for the exact device, strength, quantity, and days' supply, then get the rejection code. A formulary listing, your benefit, prior-authorization status, and a payable pharmacy claim are separate layers.

Is Zepbound coming back to CVS Caremark?

CVS Health says Zepbound will return as an additional preferred option on its most common commercial formularies on October 1, 2026, for plan sponsors that elect to cover weight-management medications. Your employer can still customize the benefit, and prior authorization can still apply.

What if I've been off Zepbound for a few months?

Caremark's shared form asks whether you received the drug within the last 120 days and whether a prior plan covered it. The form does not say that day 121 automatically makes you a new start. Count the gap, gather the last fill and old approval, and ask which written criteria your plan will use before the request is submitted.

Does CVS Caremark cover Zepbound vials or the KwikPen?

It depends on the document. The three commercial documents we read send all vials to the LillyDirect manufacturer program, and 6947-C plus 6981-A also send KwikPens there. Document 6192-C includes KwikPen quantity limits. Ask which product your policy covers before your prescriber writes the prescription.

Can Ro guarantee CVS Caremark approves Zepbound?

No. Ro says its insurance concierge can check coverage and handle prior-authorization paperwork for members seeking the Zepbound autoinjector pen, but Caremark and your plan make the coverage decision. Ro's free checker does not cover the KwikPen or vial.

Still not sure which GLP-1 program is right for you?

Take our free path-matching quiz. A few quick questions about your state, insurance, preferred medication type, treatment path, and budget — and we'll show you where to start.

Use The RX Index's Find My GLP-1 Path tool →

Free. About two minutes. No signup, no card.

Sources

All sources checked August 8, 2026 unless a different retrieval date is shown.

1. CVS Caremark — Zepbound Prior Authorization with Quantity Limit, protocol 6192-C
2. CVS Caremark — Tirzepatide Prior Authorization with Quantity Limit, protocol 6947-C
3. CVS Caremark — Tirzepatide Exception, protocol 6981-A, version 5
4. CVS Caremark — Formulary Exception / Prior Authorization Request Form
5. CVS Caremark — Prior authorization contact page
6. CVS Caremark — 2025 Indiana Annual Utilization Review Report
7. FEP Blue — Zepbound policy 5.99.031, effective July 1, 2026
8. CVS Health — Zepbound formulary announcement, May 28, 2026
9. Aetna archive — Zepbound Exception 6981-A P04-2025
10. eCFR — 29 CFR 2560.503-1, claims procedure
11. eCFR — 29 CFR 2590.715-2719, internal claims and appeals
12. eCFR — 45 CFR 147.136, internal claims, appeals, and external review
13. FDA — Zepbound prescribing information, revised February 2026
14. DailyMed — Current Zepbound product listing and NDCs
15. FDA — Mounjaro prescribing information, revised January 2026
16. FDA — Compounding and the FDA: Questions and Answers
17. CMS — Medicare GLP-1 Bridge overview
18. CMS — Medicare GLP-1 Bridge information for pharmacies and covered formulations
19. Eli Lilly — Zepbound savings and insurance options
20. Eli Lilly — LillyDirect Zepbound products and self-pay prices
21. Ro — GLP-1 Insurance Coverage Checker
22. Ro — Weight Loss Program and Insurance
23. Ro — Weight Loss Program Pricing
24. Reddit r/Zepbound — OddlyCongruent comment
25. Reddit r/Zepbound — Easy-Net6069 comment

This is general information, not medical, legal, or coverage advice. Talk with a licensed prescriber and your plan before making treatment or coverage decisions.